GERMANY: STADA SEES POTENTIAL ON FOREIGN MARKETS
Article Abstract:
In view of tightening competition in the generic drugs market, German Bad Vilbel-based Stada AG is to concentrate on new markets and expand product range with health products. Stada is to expand on the Asian market from its base in Hong Kong. The German company is also in talks about taking over a profitable US company in order to benefit from the strong growth expected on the US pharmaceutical market. In its core business of generic drugs, Stada sees growth potential in countries such as France, Spain and Italy. The company is to make further investments in these countries in drug approvals and sales and marketing. Stada expects Biogenerics AG, a company set up in the second quarter of 2000, to make profits in 2005. In the medium term, turnover should reach DM 200mn per year. In year 2000 Stada group saw a 31.8% increase in turnover to DM 913.7mn, to which generic drugs contributed DM 510.5mn, up 38.4%. Ebitda grew 43.4% to DM 106.1mn and profit for the year 62.9% to DM 36mn.
Publication Name: Chemische Rundschau
Subject: Pharmaceuticals and cosmetics industries
ISSN: 0009-2983
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
US: ROCHE JOINS SCREENING SYSTEM R&D TEAM
Article Abstract:
An electro-physiological high-performance screening system is to be developed by Axon Instruments of Foster City, California, AstraZeneca and Roche Bioscience. The Palo Alto-based subsidiary of the Swiss pharmaceutical maker joined the consortium.
Publication Name: Chemische Rundschau
Subject: Pharmaceuticals and cosmetics industries
ISSN: 0009-2983
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: GERMANY: NEW PRODUCTION PLANT FOR ASTA MEDICA. GERMANY: NUTRINOVA BETTING ON DIETARY FIBRE. US: ASTA MEDICA SELLS ABKIT TO ITALIANS
- Abstracts: GERMANY: DEGUSSA-HULS EXPANDS IN MARL. GERMANY: BASF UPS BUTYL ACRYLATE OUTPUT. GERMANY: ARYL PHOSPHATE INVESTMENT BY BAYER
- Abstracts: GERMANY: CAPITAL INJECTION TO VIROFEM. GERMANY: CANCER VACCINE TO UNDERGO TRIALS. GERMANY: CANCER DIAGNOSTICS R&D BY ADNAGEN
- Abstracts: GERMANY: ACORDIS HIVES OFF LOGISTICS. GERMANY: CONSTRUCTION CHEMICALS R&D BY SKW. GERMANY: LOGISTICS INVESTMENT BY BASF
- Abstracts: GERMANY: ECI, HERAEUS INVESTING IN BITTERFELD. GERMANY: KUHNE & NAGEL EXPANDS IN DUISBURG. GERMANY: HERAEUS QUARZ GLASS INVESTMENT